Active Ingredient: BORTEZOMIB
Proprietary Name: BORTEZOMIB
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
Strength: 3.5MG/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A205857
Product Number: 001
Approval Date: May 2, 2022
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA INC
Marketing Status:
Discontinued
Patent and Exclusivity Information